Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition

被引:29
|
作者
Chen, Mengqian [1 ]
Li, Jing [1 ]
Liang, Jiaxin [1 ]
Thompson, Zanshe S. [2 ]
Kathrein, Katie [3 ]
Broude, Eugenia, V [1 ]
Roninson, Igor B. [1 ]
机构
[1] Univ South Carolina, Coll Pharm, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA
[2] Univ South Carolina, Coll Engn & Comp, Dept Biomed Engn, Columbia, SC 29208 USA
[3] Univ South Carolina, Dept Biol, Columbia, SC 29208 USA
关键词
CDK8; CDK19; kinome profiling; zebrafish toxicity assays; STAT1 serine phosphorylation; DEPENDENT KINASE 8; POTENT; DISCOVERY; PHOSPHORYLATION; TRANSCRIPTION; CORTISTATIN; STAT1;
D O I
10.3390/cells8111413
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
CDK8/19 kinases, which mediate transcriptional reprogramming, have become an active target for cancer drug discovery. Several small-molecule CDK8/19 inhibitors showed in vivo efficacy and two have entered clinical trials, with no significant toxicities reported. However, Clarke et al. (eLife 2016; 5; e20722) found severe systemic toxicity associated with two potent CDK8/19 inhibitors, Cmpd3 (CCT251921) and Cmpd4 (MSC2530818), and suggested that their toxicity was due to on-target effects. Here, we compared five CDK8/19 inhibitors: Cmpd3, Cmpd4, Senexin B, 16-didehydro-cortistatin A (dCA) and 15w, in different assays. Only Cmpd4 showed striking toxicity in developing zebrafish. In cell-based assays for CDK8 and CDK19 inhibition, Cmpd3, Cmpd4, dCA and 15w showed similar low-nanomolar potency and efficacy against CDK8 and CDK19, while Senexin B was less potent. Only dCA produced sustained inhibition of CDK8/19-dependent gene expression. While toxicity of different compounds did not correlate with their effects on CDK8 and CDK19, kinome profiling identified several off-target kinases for both Cmpd3 and Cmpd4, which could be responsible for their toxicity. Off-target activities could have been achieved in the study of Clarke et al. due to high in vivo doses of Cmpd3 and Cmpd4, chosen for the ability to inhibit STAT1 S727 phosphorylation in tumor xenografts. We show here that STAT1 S727 phosphorylation is induced by various cytokines and stress stimuli in CDK8/19-independent manner, indicating that it is not a reliable pharmacodynamic marker of CDK8/19 activity. These results illustrate the need for careful off-target analysis and dose selection in the development of CDK8/19 inhibitors.
引用
收藏
页数:17
相关论文
共 4 条
  • [1] Discovery of CCT251921: A potent, selective and orally bioavailable small molecule modulator of the mediator complex-associated kinases CDK8 and CDK19
    Mallinger, Aurelie
    Schiemann, Kai
    Rink, Christian
    Stieber, Frank
    Calderini, Michel
    Stubbs, Mark
    Poeschke, Oliver
    Busch, Michael
    Czodrowski, Paul
    Musil, Djordje
    Schwarz, Daniel
    Ortiz-Ruiz, Maria-Jesus
    Schneider, Richard
    Valenti, Melanie
    Brandon, Alexis de Haven
    Workman, Paul
    Dale, Trevor
    Wienke, Dirk
    Clarke, Paul
    Esdar, Christina
    Raynaud, Florence
    Eccles, Suzanne
    Rohdich, Felix
    Blagg, Julian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [2] CDK8/CDK19 inhibition as therapeutic target of metastatic prostate cancer
    Offermann, A.
    Becker, F.
    Kluemper, N.
    Vogel, W.
    Braegelmann, J.
    Perner, S.
    VIRCHOWS ARCHIV, 2017, 471 : S269 - S269
  • [3] Preventing adaptive therapeutic resistance to CDK4/6 inhibition with CDK8/19 inhibitors
    Mack, Zachary
    Yastrebova, Margarita
    Khamidullina, Alvina
    Sharko, Amanda
    Ding, Xiaokai
    Bowe, Stephan
    Sashi, Nikitha
    Safa, Samantha
    Digsby, Kaitlyn
    Eckstrom, Amanda
    Sikirzhitski, Vitali
    Lim, Chang-Uk
    Tatarskiy, Victor
    Roninson, Igor
    Broude, Eugenia
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential
    Fujimoto, Jun
    Hirayama, Takaharu
    Hirata, Yasuhiro
    Hikichi, Yukiko
    Murai, Saomi
    Hasegawa, Maki
    Hasegawa, Yuka
    Yonemori, Kazuko
    Hata, Akito
    Aoyama, Kazunobu
    Cary, Douglas R.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (12) : 3018 - 3033